FRC
FRC Logo
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us

Resources

  • Videos
  • Research Reports
  • FAQ

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Research
Get Access
Sign In
Shuttle Pharmaceuticals Holdings, Inc. Stock AnalysisComprehensive stock analysis for Shuttle Pharmaceuticals Holdings, Inc. (SHPH) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisSHPH
SHPH
Shuttle Pharmaceuticals Holdings, Inc.
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
SHPH
Home🔹Stocks🔹Shuttle Pharmaceuticals Holdings, Inc.

Shuttle Pharmaceuticals Holdings, Inc.

SHPH•NASDAQ

Shuttle Pharmaceuticals Holdings, Inc.

SHPH•NASDAQ
Market cap
$1.63M
Sentiment

Your view on SHPH

Mkt Cap
$1.63M
Sentiment
Your view
SHPH
Shuttle Pharmaceuticals Holdings, Inc.
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
SHPH
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Shuttle Pharmaceuticals Holdings, Inc.

Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
CEO
Christopher Robert Cooper BBA, MBA
Headquarters
One Research Court, Gaithersburg, MD, US
Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
CEO
Christopher Robert Cooper BBA, MBA
Headquarters
One Research Court, Gaithersburg, MD, US
Description

Shuttle Pharmaceuticals Holdings, Inc., through its subsidiary, Shuttle Pharmaceuticals, Inc., focuses on the discovery, development, and commercialization of drugs for sensitizing cancers to radiation therapy. Its products in clinical stage include Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and soft tissue sarcomas; and Doranidazole, an injectable hypoxic cell radiation sensitizer for treatment of pancreatic, lung, and liver cancers. The company was founded in 2012 and is based in Rockville, Maryland.

Infographics

Visual summary of the business at a glance.

FRC Research

Media

Videos and interviews covering the company.

Financial Data

Stock Data

Price chart, volume, and trading data.

Fair Value

What FRC thinks the stock is worth vs. the current price.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

Financial Statements

Income statement, balance sheet, and cash flow statements.

Peer Comparison

Comparables

List of peer companies in the same industry.

Ownership & News

Institutional Ownership

Which funds and firms own the stock.

Insider Trading

Recent buying and selling by company executives.

Senate Trading

U.S. Senator disclosures filed under the STOCK Act.

News

Latest headlines and market coverage.

News

Latest Market News